Champion Platform: Drug treatment study (Cangrelor) for patients needing coronary angioplasty or stenting

The purpose of this study is to determine the effectiveness of an experimental new intravenous (IV) drug, called Cangrelor, in treating people with heart disease who need a percutaneous coronary intervention (angioplasty or stent).  Overall, 4,400 patients will be recruited for this study. At Rush University Medical Center in Chicago, Illinois, we expect to recruit approximately 50 patients. The treatment (Cangrelor or placebo) will be assigned randomly in a 1:1 ratio.

You may be eligible for this study if you:

• Are male or a nonpregnant female 18 years of age or older
• Have been diagnosed with coronary artery disease or have suspected coronary stenosis
• Have had a diagnostic coronary angiography demonstrating blockage amenable to treatment by PCI with or without stent implantation

You are not eligible for this study if you:

• Are not a candidate for PCI
• Have taken clopidogrel (Plavix) 7 days prior to entering the study
• Have inadequately controlled severe high blood pressure
• Have had a planned staged PCI procedure where the second stage will occur less than 30 days after the first intervention
• Have an increased bleeding risk
• Have an INR value greater than 1.5
• Have an allergy or hypersensitivity to cangrelor, mannitol, or sorbitol

This is a partial list of eligibility and exclusion criteria. To determine if you are eligible to participate, please call the contact phone number provided. If you choose to respond by e-mail, please refer to the title of the study in your correspondence.